Masimo (NASDAQ:MASI) Sets New 52-Week High - Should You Buy?

Key Points

• New 52-week high: Masimo traded as high as $176.19 (last $175.97) on Wednesday with about 3.64 million shares changing hands.
• Analyst consensus: Hold — the street breakdown is 1 Buy, 7 Hold, 1 Sell with an average price target of $181.17, and several firms recently downgraded or trimmed targets to roughly $180.
• Company fundamentals: market cap $9.45 billion, P/E -16.70, 50-day / 200-day moving averages $153.41 / $146.40 (both below the current price), and institutional ownership of 85.96%.

Masimo Corporation (NASDAQ:MASI - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $176.19 and last traded at $175.97, with a volume of 3642133 shares. The stock had previously closed at $175.40.

Wall Street Analyst Weigh In

MASI has been the topic of several recent analyst reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Masimo in a report on Thursday, January 22nd. Wells Fargo & Company cut shares of Masimo from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $190.00 to $180.00 in a report on Wednesday, February 18th. Wolfe Research downgraded Masimo from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 19th. Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday, February 17th. Finally, Piper Sandler cut Masimo from an "overweight" rating to a "hold" rating and set a $180.00 price objective for the company. in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $181.17.

Masimo Price Performance

The firm has a market cap of $9.45 billion, a P/E ratio of -16.70, a price-to-earnings-growth ratio of 1.78 and a beta of 1.21. The stock's 50-day moving average is $153.41 and its 200-day moving average is $146.40. The company has a quick ratio of 1.47, a current ratio of 2.49 and a debt-to-equity ratio of 0.72.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider's stock valued at $1,894,000 after buying an additional 66 shares during the period. Clearstead Advisors LLC grew its position in Masimo by 18.4% during the third quarter. Clearstead Advisors LLC now owns 470 shares of the medical equipment provider's stock worth $69,000 after buying an additional 73 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Masimo by 12.9% during the fourth quarter. Hantz Financial Services Inc. now owns 655 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 75 shares during the period. Assetmark Inc. raised its holdings in Masimo by 5.5% in the 4th quarter. Assetmark Inc. now owns 1,850 shares of the medical equipment provider's stock valued at $241,000 after acquiring an additional 97 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Masimo by 5.3% in the 2nd quarter. ProShare Advisors LLC now owns 1,995 shares of the medical equipment provider's stock worth $336,000 after buying an additional 101 shares in the last quarter. Institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.